Outlook Therapeutics Receives European Authorization for LYTENAVA™

FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 – JTC Team, a corporate communications and investor relations firm, has released a "What This Means" segment featuring Outlook Therapeutics, Inc. (Nasdaq:OTLK). The segment highlights the European Commission Marketing Authorization granted to Outlook Therapeutics for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD.

Russell Trenary, President and CEO of Outlook Therapeutics, emphasized the significance of LYTENAVA™ as the first ophthalmic formulation of bevacizumab to obtain this authorization. This marks a key milestone in the company’s efforts in the commercialization and development of treatments for retina diseases.

The "What This Means" segment can be viewed on the Virtual Investor platform. Additional videos from the series are also available on demand.